Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | -4.07% | -14.03% | -85.57% |
May. 14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
May. 10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.57% | 129M | |
+16.60% | 124B | |
+17.07% | 109B | |
-7.24% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.56% | 16.61B | |
-37.63% | 16.43B | |
+1.59% | 13.4B | |
+23.61% | 11.47B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15